<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622409</url>
  </required_header>
  <id_info>
    <org_study_id>T3322</org_study_id>
    <nct_id>NCT05622409</nct_id>
  </id_info>
  <brief_title>A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma</brief_title>
  <official_title>A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioma is a major histological subtype of primary malignant brain tumors in Taiwan, with&#xD;
      distinct epidemiological, clinical, and pathological features comparing to the other common&#xD;
      cancer diseases. The disease rarely appears with metastatic disease at diagnosis, and with&#xD;
      the most malignant subtype, glioblastoma, occurs with preference in mid- to old-age. For&#xD;
      decades, primary malignant brain tumors has been known as one of the most desperate disease&#xD;
      without successful improvement regarding of the treatment. Surgical resection is the&#xD;
      principle for the primary treatment of gliomas. Chemotherapy and radiotherapy are often&#xD;
      applied to patients for adjuvant therapy of surgery to pursue the treatment effect.&#xD;
      Disappointedly, vast majority of the patients would eventually develop disease recurrence,&#xD;
      leaving only limited choice for salvage treatment thereafter. The prognosis of these patients&#xD;
      remains desperate, and thus a better understanding of this deadly disease is crucial for&#xD;
      finding better therapeutic strategies for these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With demand of molecular characterization in precise diagnosis, we proposed this registry&#xD;
      study to explore the impact of the new criteria by applying next-generation sequencing. The&#xD;
      specific aims of this project are (1) to establish the tumor genetic and molecular profiles&#xD;
      of adult-type diffuse gliomas in Taiwan, (2) to understand the treatment prognosis depending&#xD;
      on difference of the genetic and molecular profiles for adult-type diffuse gliomas in Taiwan,&#xD;
      and (3) to reveal the evolutionary changes of genetic and molecular features of adult-type&#xD;
      diffuse gliomas. The long-term goals of this study are to help implement personalized&#xD;
      therapy, to develop novel therapy, and to improve outcomes of patients with adult-type&#xD;
      diffuse gliomas. It is also expected to create a platform for data storage and sharing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the genetic profiles in advanced thyroid cancer patients in Taiwan.</measure>
    <time_frame>5 years</time_frame>
    <description>ACTonco+ACTFusion Biospecimen Retention: Samples With DNA One H&amp;E staining slide, and 15-20 tissue slides (5 um thickness) for cancer panel.&#xD;
Details of Tests/Collaborative Test Unit:&#xD;
Testing will take place in a certified precision medicine laboratory.&#xD;
Non-tumor Sample (Blood): Seven(7)ml of cell free DNA and Eight (8) ml of blood in EDTA tube will be collected from the participant</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">275</enrollment>
  <condition>Primary Malignant Brain Tumors</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <description>Newly diagnosis arm (N=150): The study aims to obtain clinical information to correlate with genetic characterization of ATDGs of all types. Only patients with primary tumors that have recently received surgery are applicable.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <description>Post treatment arm 1 for training set (IDH-wild type ATDGs, N=50; IDH-mutant ATDGs, N=50): The study aims to compare the genetic differences of ATDGs in terms of IDH mutation status. Samples of primary tumors are preferred but can be replaced with recurrent ones. Paired samples are both eligible for typing if the recurrent diseases of IDH-mutant tumors possess potential altered genes (such as up grading per histology features).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <description>Post treatment arm 2 (recurrent ATDGs; N=25): The study will focus on recurrent diseases of ATDGs to study the consistency of genetic difference of the primary and the recurrent tumors. Tumor free is mandatory and needs to be documented after resection of the primary tumor. Patients remain eligible if IDH statuses are uncertain.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma</intervention_name>
    <description>A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. One H&amp;E staining slide, and 15-20 tissue slides (5 um thickness) for cancer panel.&#xD;
&#xD;
        2. Details of Tests/Collaborative Test Unit:&#xD;
&#xD;
           Testing will take place in a certified precision medicine laboratory.&#xD;
&#xD;
        3. Non-tumor Sample (Blood): Fifteen (15) ml of blood will be collected from the&#xD;
           participant: 7 ml in EDTA tube (purple top) and 8 ml in Cell-Free DNA blood collection&#xD;
           tube.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Arm 1: (Newly diagnosis arm): Anticipated 150 patients. Arm 2: IDH expression (N=50 for&#xD;
        IDH-mutant and N=50 for IDH-wild type) Arm 3:Recurrent and paired samples (N=25).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pathological confirmation or suggestion of adult-type diffuse gliomas A. Diagnosis&#xD;
             includes glioblastoma, astrocytoma, oligodendrocytoma that is listed in ATDG category&#xD;
             per WHO criteria.&#xD;
&#xD;
             B. Gliomas that are preferred as ATDGs from pathological and clinical views, but not&#xD;
             given for confirmed diagnosis.&#xD;
&#xD;
          2. Willingness to provide archival or newly obtained tumor tissues for current study&#xD;
             proposal.&#xD;
&#xD;
          3. Age equal or more than 20 years old (inform consent).&#xD;
&#xD;
          4. Life expectancy more than 3 months.&#xD;
&#xD;
          5. Patients fully understand the protocol with the willingness to have regular follow-up.&#xD;
&#xD;
          6. Additional criteria for individual arms A. [Arm 1] Within 2 months after surgery for&#xD;
             primary tumor. B. [Arm 2] Total resection of primary tumors with tissue samples&#xD;
             available for test.&#xD;
&#xD;
        C. [Arm 3] (1) Total resection of primary tumors with the paired primary and recurrent&#xD;
        tissue samples available for test. (2) IDH test suggesting wild-type.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Gliomas diagnosed or preferred as other categories than ATDGs, such as pediatric-type&#xD;
             diffuse gliomas, circumscribed astrocytic gliomas, and others.&#xD;
&#xD;
          2. Inability to cooperate by providing a complete medical history.&#xD;
&#xD;
          3. Patients disagree to provide archived tumor samples.&#xD;
&#xD;
          4. Undesirable compliance.&#xD;
&#xD;
          5. Having a known additional malignancy that is progressing or has required active&#xD;
             treatment within the past 3 years. Participants with basal cell carcinoma of the skin,&#xD;
             squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in&#xD;
             situ) that have undergone potentially curative therapy are not excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Chien-Ya Hung</last_name>
    <phone>+886-3-7206166</phone>
    <phone_ext>35104</phone_ext>
    <email>951106@nhri.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kwang-Yu Chang</last_name>
    <phone>+886-6-7000123</phone>
    <phone_ext>65112</phone_ext>
    <email>960826@nhri.edu.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming-Jung Chuang</last_name>
    </contact>
    <investigator>
      <last_name>Ming-Jung Chuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shuang Ho Hospital</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong-Kwang Tu</last_name>
    </contact>
    <investigator>
      <last_name>Yong-Kwang Tu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Chung Chen</last_name>
    </contact>
    <investigator>
      <last_name>Chun-Chung Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiung-Chyi Shen</last_name>
    </contact>
    <investigator>
      <last_name>Chiung-Chyi Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E-Jian Lee</last_name>
    </contact>
    <investigator>
      <last_name>E-Jian Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dar-Ming Lai</last_name>
    </contact>
    <investigator>
      <last_name>Dar-Ming Lai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yung-Hsiao Chiang</last_name>
    </contact>
    <investigator>
      <last_name>Yung-Hsiao Chiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanford PC Hsu</last_name>
    </contact>
    <investigator>
      <last_name>Sanford PC Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHENG GUNG MEMORIAL HOSPITAL, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>kuo-chen wei</last_name>
    </contact>
    <investigator>
      <last_name>kuo-chen wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>November 13, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>May 8, 2023</last_update_submitted>
  <last_update_submitted_qc>May 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult-type diffuse gliomas</keyword>
  <keyword>next-generation sequencing</keyword>
  <keyword>precision medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

